Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

Trial Profile

Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms METREO
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 May 2018 Results of a pre-specified meta-analysis (n= 1136) assessing the effect of mepolizumab on patient-reported outcomes, response to therapy and lung function using combined data from METREX and METREO trials, presented at the 114th International Conference of the American Thoracic Society.
    • 07 Nov 2017 According to a GlaxoSmithKline media release, based on the data from METREX and METREO studies the company has submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA), seeking approval of mepolizumab as an add-on to maintenance treatment for patients who have chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. Regulatory filings in other countries are planned during the course of 2017 and 2018.
    • 13 Sep 2017 According to a GlaxoSmithKline media release, results of the METREX and METREO studies, along with data from a pre-specified meta-analysis combining both studies, have been published in the New England Journal of Medicine (NEJM), with simultaneous presentation at the European Respiratory Society (ERS) International Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top